Metropolis Healthcare Limited has informed the Exchange about Investor Presentation
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Metropolis Healthcare reported robust Q4FY26 and FY26 results. MHL Group revenue grew 23% YoY to Rs.425 Cr in Q4 and 24% YoY to Rs.1,646 Cr for FY26. EBITDA grew 71% YoY in Q4 and 31% YoY for FY26, with EBITDA margins expanding to 27.2% in Q4FY26 and 25.9% for FY26 (organic basis). Patient volumes grew 9.3% YoY in Q4 with revenue per patient up 5%. Both B2C (14% YoY) and B2B (13% YoY) segments delivered strong growth, while TruHealth and Specialty segments grew 21% and 16% respectively. The company expanded to ~750 towns with 5,026 service network points. Acquisitions (Core Diagnostics, DAPIC, Scientific Pathology, Ambika) contributed 8% of total FY26 revenue with integration on track. The company reiterated its Metropolis 3.0 strategy targeting mid-teen revenue CAGR from FY23-26 and pre-Covid margin profile restoration.
Positive for shareholders - strong revenue growth combined with significant margin expansion demonstrates operating leverage. The company is on track to achieve its strategic targets. Acquisitions are being integrated smoothly and contributing to growth. Stock appears well-positioned given consistent execution and expanding profitability.